Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Hero

Showing results (91-100 of 141) with videos related to

Pageof 15
Sort By:
Current Oncology (Toronto, Ont.)|November 10, 2022
Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg RegistryDanny Jazmati, Barbara Hero, Theresa M Thole-Kliesch, et al.
Molecular Oncology|November 25, 2015
Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastomaFakhera Ikram, Sandra Ackermann, Yvonne Kahlert, et al.
Frontiers in Endocrinology|July 5, 2022
Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma-Experiences From the GPOH-MET RegistryMichaela Kuhlen, Christina Pamporaki, Marina Kunstreich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group projectKieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.
Pediatric Blood & Cancer|March 4, 2014
Rare malignant pediatric tumors registered in the German Childhood Cancer Registry 2001-2010Ines B Brecht, Claudia Bremensdorfer, Dominik T Schneider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2018
LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic GlycolysisCarmen Dorneburg, Matthias Fischer, Thomas F E Barth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group DatabaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2012
A three-gene expression signature model for risk stratification of patients with neuroblastomaIdoia Garcia, Gemma Mayol, José Ríos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force reportSusan L Cohn, Andrew D J Pearson, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastomaJohannes H Schulte, Hagen S Bachmann, Bent Brockmeyer, et al.
Pageof 15

Showing results (91-100 of 141) with videos related to

Sort By:
Pageof 15
Current Oncology (Toronto, Ont.)|November 10, 2022
Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg RegistryDanny Jazmati, Barbara Hero, Theresa M Thole-Kliesch, et al.
Molecular Oncology|November 25, 2015
Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastomaFakhera Ikram, Sandra Ackermann, Yvonne Kahlert, et al.
Frontiers in Endocrinology|July 5, 2022
Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma-Experiences From the GPOH-MET RegistryMichaela Kuhlen, Christina Pamporaki, Marina Kunstreich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group projectKieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.
Pediatric Blood & Cancer|March 4, 2014
Rare malignant pediatric tumors registered in the German Childhood Cancer Registry 2001-2010Ines B Brecht, Claudia Bremensdorfer, Dominik T Schneider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2018
LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic GlycolysisCarmen Dorneburg, Matthias Fischer, Thomas F E Barth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group DatabaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2012
A three-gene expression signature model for risk stratification of patients with neuroblastomaIdoia Garcia, Gemma Mayol, José Ríos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force reportSusan L Cohn, Andrew D J Pearson, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastomaJohannes H Schulte, Hagen S Bachmann, Bent Brockmeyer, et al.
Pageof 15